Health ❯ Healthcare ❯ Oncology

Chronic Lymphocytic Leukemia

BRUKINSA BTK Inhibitors Bruton Tyrosine Kinase Inhibitors Treatment Strategies Adverse Effects Management Dose Modification Strategies Long-term Treatment Outcomes Patient Management Zanubrutinib Risk Factors Treatment Approaches Treatment Outcomes Patient Decision-Making Pirtobrutinib Treatment Regimens Treatment Advances Jaypirca Treatment CLL14 Trial

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

The ruling rests on AMPLIFY Phase III results showing superior progression-free survival to chemoimmunotherapy.

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy